Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genentech Restricts Population In Last-Ditch Bid To Keep Avastin's Breast Cancer Claim

This article was originally published in The Pink Sheet Daily

Executive Summary

Final submission from Genentech focuses on revised indication and Risk Evaluation and Mitigation Strategy to support continued approval while it conducts another confirmatory trial.
Advertisement

Related Content

Perjeta, Avastin Breast Cancer Approvals Are A Study In Contrasts
Oncology Drug Applications Migrate As Part Of FDA's Reorganization Of OODP
Oncology Drug Applications Migrate As Part Of FDA's Reorganization Of OODP
Oncology Drug Applications Migrate As Part Of FDA's Reorganization Of OOP
Oncology Drug Applications Migrate As Part Of FDA's Reorganization Of OOP
Avastin Recommended For Breast Cancer Approval In Japan; Telaprevir Leads List Of Unanimous Recommendations
Genentech Losing Its Legs? Avastin Study Proposal Undercut By Feasibility, Scientific Concerns
Avastin’s Breast Cancer Claim: Will FDA’s Hamburg Take A Middle Road?
Avastin’s Breast Cancer Claim: Will FDA’s Hamburg Take A Middle Road?

Topics

Advertisement
UsernamePublicRestriction

Register

PS072733

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel